Hepatocellular carcinoma(HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early di...Hepatocellular carcinoma(HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early diagnosis are lacking. Therefore, novel biomarkers for the early detection of HCC are urgently required. Recent studies show that the abnormal release of proteins by tumor cells can elicit humoral immune responses to self-antigens called tumor-associated antigens(TAAs). The corresponding autoantibodies can be detected before the clinical diagnosis of cancer. Therefore, there is growing interest in using serum autoantibodies as cancer biomarkers. In this review, we focus on the advances in research on autoantibodies against TAAs as serum biomarker for detection of HCC, the mechanism of the production of TAAs, and the association of autoantibodies with patients' clinical characteristics.展开更多
目的：探讨血清肿瘤相关物质（TAM）和血清前列腺特异抗原（PSA）联合检测鉴别诊断前列腺疾病及前列腺癌（PCa）的临床价值。方法 TAM 采用化学显色法定量测定，PSA 采用德国罗氏公司 Cobas e 601全自动电化学发光分析仪及配套试剂检测...目的：探讨血清肿瘤相关物质（TAM）和血清前列腺特异抗原（PSA）联合检测鉴别诊断前列腺疾病及前列腺癌（PCa）的临床价值。方法 TAM 采用化学显色法定量测定，PSA 采用德国罗氏公司 Cobas e 601全自动电化学发光分析仪及配套试剂检测。结果慢性前列腺炎组、急性前列腺炎组、前列腺增生组和前列腺癌组 TAM敏感性分别为0.62%、1.94%、1.75%和94.94%，PSA 敏感性分别为40.12%、79.61%、47.81%和96.20%，PSA ﹢TAM 两项均阳性敏感性分别为0.62%、0.97%、0.88%和93.67%，TAM 特异性分别为21.33%、23.58%、25.27%和65.89%，PSA 特异性分别为47.42%、49.38%、53.62%和78.36%，PSA ﹢ TAM 两项均阳性特异性分别为20.17%、22.29%、24.56%和98.26%，差异有统计学意义（P 〈0.01）。结论 TAM 和 PSA 联合检测在敏感性和特异性上具有很好的互补作用，对鉴别诊断前列腺疾病及前列腺癌具有重要的临床价值。展开更多
基金A grant from the National Natural Science Foundation of China,No.81071973A grant from the Scientific Research Foundation for Returned Overseas Chinese Scholars,Bureau of Human Resources and Social Security of Beijing,China(Key project,2010)
文摘Hepatocellular carcinoma(HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early diagnosis are lacking. Therefore, novel biomarkers for the early detection of HCC are urgently required. Recent studies show that the abnormal release of proteins by tumor cells can elicit humoral immune responses to self-antigens called tumor-associated antigens(TAAs). The corresponding autoantibodies can be detected before the clinical diagnosis of cancer. Therefore, there is growing interest in using serum autoantibodies as cancer biomarkers. In this review, we focus on the advances in research on autoantibodies against TAAs as serum biomarker for detection of HCC, the mechanism of the production of TAAs, and the association of autoantibodies with patients' clinical characteristics.
